Upgrade to SI Premium - Free Trial

SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - Stifel

October 24, 2017 11:58 AM
Stifel analyst Thomas Shrader reiterated a Buy rating and $430 price target on Biogen (NASDAQ: BIIB) saying SPINRAZA confusion is ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles